Also categorized in BoardNews:
Six Years Later, The Problem at HP is Still the Board
x hide permanently

Sanofi is Buying Another Blood-Disease Biotech for $4.8 Billion

Business Insider
  • Sanofi is buying Belgian biotech Ablynx for $4.8 billion.
  • Ablynx had recently rejected a rival company, Novo Nordisk, after it bid $3.1 billion on the blood-disease drug developer.
  • It's Sanofi's second deal this month after it picked up Bioverativ in an $11.6 billion deal...
Mentions: Sanofi acquisition Morgan Stanley